How Mayo and nference’s JV Qrativ plans to use AI to source and develop compounds
Launched in July, Qrativ Holdings LLC is the latest venture to apply artificial intelligence to drug development, carving out a new niche by using AI to find uses for discarded early stage compounds, rather than marketed ones, and home in on an optimal path to market.
Qrativ is a JV between Mayo Clinic and AI company nference Inc., designed to combine the former’s clinical data and expertise with the latter’s intelligence platform. The company was launched with an $8.3 million series A round from Mayo, nference, Matrix Capital Management and Matrix Partners.
Activity in AI-based